Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

By sjmartinez • September 29, 2024

Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 2024 Sep 29. doi: 10.1002/cncr.35587. Epub ahead of print. PMID: 39342463.

Tags: CDK, CDK inhibition, cyclin‐dependent kinase, dinaciclib, Hematology/Oncology, melanoma, Publications

Related Posts

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Çiçin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard[...]

Local partisan context and mental health

Baxter-King R, Brown JR, Enos RD, Naeim A, Vavreck L. Local partisan context and mental health. Proc Natl Acad Sci U S A. 2026 Jul[...]

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello[...]